Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

Aspirin (acetylsalicylic acid) and intravenous immunoglobulin (IVIG) are standard treatments for Kawasaki disease (KD) to reduce coronary artery lesions (CALs). However, the optimal duration and dosage of aspirin remain inconsistent across hospitals. The absence of large-scale, multicenter randomized clinical trials hinders a clear understanding of the effectiveness of high-dose aspirin.

Objective

To evaluate the effectiveness of IVIG alone compared with IVIG combined with high-dose aspirin as the active interventional therapy for KD and to compare treatment effectiveness across various KD subgroups.

Design, setting, and participants

In this prospective, evaluator-blinded, multicenter noninferiority randomized clinical trial, children (aged <6 years) who ha

SUBMITTER: Kuo HC 

PROVIDER: S-EPMC11969286 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature